Research on the Cognitively Impaired: Lessons and Warnings from the Emergency Research Debate
- 27 April 1997
- journal article
- review article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 45 (4) , 474-481
- https://doi.org/10.1111/j.1532-5415.1997.tb05174.x
Abstract
OBJECTIVES: To demonstrate that the recent events in emergency research have broad implications for the conduct of human subjects research with the cognitively impaired. This essay illustrates the similarities between the two kinds of research and suggests how understanding these similarities might help to resolve issues in human subjects research on the cognitively impaired.METHODS: A review of pertinent journal articles, books, regulations, and court cases.RESULTS: The emergency research controversy resulted in large part because of conflicting interpretations of arguably inadequate research regulations. The proposed Food and Drug Administration (FDA) regulations include advance informed consent, a broad role for family in approving a subject's participation, replacement of a threshold of permissible risk, called minimal risk, with a more sensible balancing of risks and benefits, and a role for the community in research approval. The current state of research on the cognitively impaired suggests that many of the same problems exist now that existed in emergency research before the FDA issued its proposed regulations. The ongoing case of T.D. et al. vs N.Y. State Office of Mental Health suggests that unless steps are taken similar to those taken in emergency research, much of clinical research on the cognitively impaired could cease.CONCLUSION: Representatives of the government, medicine, and the public must recognize the unresolved issues and inadequate regulations relating to research on the cognitively impaired. The proposed FDA regulations for emergency research may provide guidance for a settlement of these issues.Keywords
This publication has 43 references indexed in Scilit:
- Advance Consent for Dementia ResearchAlzheimer Disease & Associated Disorders, 1994
- Surrogate Decision Making for Severely Cognitively Impaired Research Subjects: The Continuing DebateCambridge Quarterly of Healthcare Ethics, 1994
- NGF and the Treatment of Alzheimer's DiseaseExperimental Neurology, 1993
- Informed consent for biomedical research in acute care medicineAnnals of Emergency Medicine, 1991
- Clinical Safety, Tolerance, and Plasma Levels of the Oral Anticholinesterase 1,2,3,4-Tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's Disease: Preliminary FindingsThe Journal of Clinical Pharmacology, 1990
- Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's DiseaseNew England Journal of Medicine, 1990
- Equipoise and the Ethics of Clinical ResearchNew England Journal of Medicine, 1987
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- A Trial Policy for the Intramural Programs of the National Institutes of Health: Consent to Research with Impaired Human SubjectsIRB: Ethics & Human Research, 1985